普拉克索片联合美多芭治疗帕金森病的疗效分析

Effect analysis of pramipexole tablets combined with Medoba in the treatment of Parkinson’s disease

目的探讨普拉克索片联合多巴丝肼片(商品名:美多芭)治疗帕金森病的疗效。方法88例帕金森病患者,随机分为研究组和对照组,每组44例。研究组患者给予普拉克索片联合美多芭治疗,对照组患者给予美多芭单药治疗。比较两组患者治疗前后统一帕金森病评定量表(UPDRS)评分、简易精神状态评价量表(MMSE)评分和临床疗效、不良反应发生情况。结果治疗后,研究组患者UPDRS评分(35.22±6.35)分明显低于对照组的(38.05±6.49)分,MMSE评分(26.38±4.69)分明显高于对照组的(23.29±3.19)分,差异具有统计学意义(P<0.05)。研究组患者总有效率为86.4%,明显高于对照组的68.2%,差异具有统计学意义(P<0.05)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论普拉克索片联合美多芭治疗帕金森病可明显改善患者的运动症状与认知功能。

Objective To discuss the efficacy of pramipexole tablets combined with levodopa and benserazide hydrochloride tablets(trade name:Medoba)in the treatment of Parkinson’s disease.Methods A total of 88 patients with Parkinson’s disease were randomly divided into research group and control group,with 44 cases in each group.The research group was treated with pramipexole tablets combined with Medoba,and the control group was treated with Medoba.The Unified Parkinson’s Disease Rating Scale(UPDRS)score,mini-mental state assessment(MMSE)score before and after treatment,clinical efficacy and occurrence of adverse reactions were compared between the two groups.Results After treatment,the UPDRS score(35.22±6.35)points of the research group was obviously lower than(38.05±6.49)points of the control group,and MMSE score(26.38±4.69)points was obviously higher than(23.29±3.19)points of the control group,and the difference was statistically significant(P<0.05).The total effective rate of the research group was 86.4%,which was obviously higher than 68.2%of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of adverse reactions between the two groups(P>0.05).Conclusion Pramipexole tablets combined with Medoba can obviously improve the motor symptoms and cognitive function of patients with Parkinson’s disease.